Latest From CeramTec AG
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
China’s leading medical device company enters the orthopedic market with a $35.5 million acquisition of domestic player Dragonbio.
One of the most innovative and creative orthopedic implant designers, the UK's Finsbury's Orthopedics never quite built the sales and distribution capability to enable it to capture the full value of its designs. The company's recent sale to DePuy underscores how much the orthopedics industry has changed since its earliest days.
Amedica says its high-strength silicon nitride-based ceramic could be the answer to some of the more vexing problems in spine, hip and knee surgeries. But can this materials science expert become a real orthopedics company?
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- CeramTec AG
- Senior Management
Ulf D Zimmermann , PhD, CEO
Rolf-Michael Müller , CFO
- Contact Info